Of these, the cytidine analogues 5-azacytidine (5-Aza-CR) and 5-aza-2′-deoxycytidine (5-Aza-CdR) are the two most potent DNMT inhibitors and have been approved by the Food and Drug Administration (FDA) in the USA for the treatment of myeloid malignancies and other solid tumors91–93. Here, DNMT1 is linked to myeloid neoplasm.